Karuna Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Karuna Therapeutics

23/02/2024 03:02

* Karuna Therapeutics Inc  KRTX.OQ  reported a quarterly
adjusted
loss of $3.01​​ per share for the quarter ended in December,
lower than the same quarter last year, when the company reported
EPS of $-2.22.  The mean expectation of twenty analysts for the
quarter was for a loss of $2.65 per share. Wall Street expected
results to range from $-3.79 to $-2.12 per share.
    * Reported revenue was zero​; analysts expected $761.18
thousand. 
    * Karuna Therapeutics Inc's reported EPS for the quarter was
a
loss of $3.01​.
    * The company reported a quarterly loss of $113.82 million.
    * Karuna Therapeutics Inc shares had risen by 0.8% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 1% in
the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 15
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "hold"

Wall Street's median 12-month price target for Karuna
Therapeutics Inc is $330.00 
This summary was machine generated from LSEG data February 23 at
03:01 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -2.65          -3.01          Missed
 Sep. 30 2023      -2.74          -3.16          Missed
 Jun. 30 2023      -2.78          -2.75          Beat
 Mar. 31 2023      -2.76          -2.80          Missed